Royalty Pharma plc

RPRXSEC EDGAR

Pharmaceutical Preparations(X0)CIK: 1802768

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$2.4B	$2.2B	$2.3B	$2.1B	$1.8B
Research and Development Expense	$52.0M	$177.1M	$200.1M	$26.3M	$83.0M
Operating Income (Loss)	$1.5B	$307.1M	$1.4B	$1.6B	$2.6B
Interest Expense	—	—	$166.1M	$157.1M	$268.6M
Nonoperating Income (Expense)	$207.9M	-$77.0M	-$189.5M	$106.6M	-$161.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$1.7B	$230.1M	$1.2B	$1.7B	$2.5B
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$18.2B	$16.4B	$16.8B	$17.5B	$16.0B
Assets, Current	$1.8B	$1.3B	$2.6B	$2.9B	$2.7B
Cash and Cash Equivalents, at Carrying Value	$929.0M	$477.0M	$1.7B	$1.5B	$1.0B
Liabilities	$7.9B	$6.3B	$7.3B	$7.3B	$6.1B
Liabilities, Current	$1.3B	$161.4M	$1.2B	$171.3M	$307.9M
Long-term Debt	$7.6B	$6.1B	$7.1B	$7.1B	$5.8B
Weighted Average Number of Shares Outstanding, Basic	$447.6M	$438.0M	$414.8M	$375.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$3.0B	$2.1B	$2.0B	$2.0B	$1.7B
Net Cash Provided by (Used in) Investing Activities	-$2.1B	-$1.0B	-$1.9B	-$2.8B	-$2.2B
Net Cash Provided by (Used in) Financing Activities	-$2.1B	-$944.9M	$385.1M	$1.5B	-$1.2B
Payments for Repurchase of Common Stock	$304.8M	$0.00	$0.00	—	$4.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)